Horizon Therapeutics Public Limited Company (HZNP)

92.14 +4.40 (+5.01%) At close: 4:00PM EDT

Horizon Therapeutics Public Limited Company

Connaught House
1st Floor 1 Burlington Road
Dublin 4
Ireland
353 1 772 2100
http://www.horizontherapeutics.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 1,640

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Timothy P. Walbert	Chairman, Pres & CEO	5.48M	N/A	1967
Mr. Paul W. Hoelscher	Exec. VP & CFO	1.88M	N/A	1965
Mr. Barry J. Moze	Exec. VP & Chief Admin. Officer	1.71M	1.35M	1954
Dr. Jeffrey W. Sherman M.D., F.A.C.P.	Exec. VP & Chief Medical Officer	1.55M	2.3M	1955
Mr. Andy Pasternak	Exec. VP & Chief Strategy Officer	1.79M	N/A	1971
Mr. Miles W. McHugh	Chief Accounting Officer & Sr. VP	N/A	N/A	1965
Ms. Tina E. Ventura	Sr. VP of Investor Relations	N/A	N/A	N/A
Mr. Brian K. Beeler	Exec. VP & Gen. Counsel	N/A	N/A	1973
Mr. Timothy Ayers	Chief Compliance Officer & VP	N/A	N/A	N/A
Mr. Geoffrey M. Curtis	Exec. VP of Corp. Affairs & Chief Communications Officer	N/A	N/A	1975

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Corporate Governance

Horizon Therapeutics Public Limited Company’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.